Table 1.
Patient and disease characteristics at initiation of targeted therapy (n=2,027).
| Characteristic | n (%) |
|---|---|
|
| |
| Age at initiation of therapy | |
| < 60 years | 945 (47%) |
| ≥60 years | 1,082 (53%) |
|
| |
| Karnofsky performance score | |
| ≥ 80% | 1,465 (72%) |
| < 80% | 445 (22%) |
| Unknown | 117 (6%) |
|
| |
| Sex | |
| Male | 1,494 (74%) |
| Female | 524 (26%) |
| Unknown | 9 (<1%) |
|
| |
| Pathology | |
| Clear cell | 1,661 (82%) |
| Non-clear cell | 238 (12%) |
| Unknown | 128 (6%) |
|
| |
| Sarcomatoid features | |
| Yes | 185 (9%) |
| No | 1,599 (79%) |
| Unknown | 243 (12%) |
|
| |
| Previous nephrectomy | |
| Yes | 1,570 (78%) |
| No | 455 (22%) |
| Unknown | 2 (<1%) |
|
| |
| Previous immunotherapy | |
| Yes | 444 (22%) |
| No | 1,583 (78%) |
|
| |
| Type of targeted agent | |
| Sunitinib | 1491 (74%) |
| Sorafenib | 357 (18%) |
| Bevacizumab | 80 (4%) |
| Pazopanib | 40 (2%) |
| Tivazonib | 7 (<1%) |
| Axitinib | 3 (<1%) |
| Temsirolimus | 42 (2%) |
| Everolimus | 7 (<1%) |
|
| |
| Number of metastases > 1 | 1,529 (75%) |
|
| |
| Metastasis site | |
| Lung | 1,390 (69%) |
| Lymph node | 864 (43%) |
| Bone | 693 (34%) |
| Liver | 381 (19%) |
| Brain | 165 (8%) |
| Other | 713 (35%) |
|
| |
| IMDC risk group | |
| Favorable | 321 (16%) |
| Intermediate | 969 (48%) |
| Poor | 504 (25%) |
| Unknown | 233 (11%) |